(CYBN) –
-
Form SC 13G CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CYBIN INC. Filed by: Deep Track Capital, LP
-
Form 6-K CYBIN INC. For: Mar 21
-
Form 6-K CYBIN INC. For: Mar 21
-
Form 6-K CYBIN INC. For: Mar 20
-
Cybin Inc (CYBN) Closes $150M Share Placement
-
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
-
Form 6-K CYBIN INC. For: Mar 18
-
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
-
Form 6-K CYBIN INC. For: Mar 15
-
Cybin (CYBN) Initiates Phase 2 Proof-of-Concept Study of CYB004
-
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
-
Form 6-K CYBIN INC. For: Mar 14
-
Cybin Inc (CYBN) Reports Positive End-of-Phase 2 Meeting with FDA for CYB003
-
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
-
Form 6-K CYBIN INC. For: Mar 13
-
Form 6-K CYBIN INC. For: Mar 12
-
Cybin Inc (CYBN) Announces $150M Oversubscribed Private Placement at $0.43/sh
-
Announces Oversubscribed Private Placement of U.S. $150 Million
-
Cybin Inc (CYBN) Receives FDA Breakthrough Therapy Designation for CYB003
-
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
-
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
-
Form 6-K CYBIN INC. For: Feb 27
-
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
-
Cybin Inc. (CYBN) PT Lowered to $4 at Canaccord Genuity
-
Form 6-K/A CYBIN INC. For: Feb 14
-
Form SC 13G/A CYBIN INC. Filed by: Point72 Asset Management, L.P.
-
Form 6-K CYBIN INC. For: Feb 14
-
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
-
Form 6-K CYBIN INC. For: Feb 07
-
Cybin Inc (CYBN) Granted Two Additional Patents in Japan in Support of DMT Program
-
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
-
Form 6-K CYBIN INC. For: Jan 23
-
Cybin Inc (CYBN) Granted FDA Clearance to Initiate a Phase 2a Study of CYB004
-
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
-
Form 6-K CYBIN INC. For: Jan 08
-
Cybin Inc (CYBN) Reports Positive Topline Data from Phase 1 Studies of CYB004 and SPL028
-
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
-
Form 6-K CYBIN INC. For: Jan 04
-
Cybin Inc (CYBN) Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
-
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
-
Form EFFECT CYBIN INC.
-
Form F-X CYBIN INC. Filed by: CYBIN INC.
-
Form F-10 CYBIN INC.
-
Form 6-K CYBIN INC. For: Dec 06
-
Cybin Inc (CYBN) Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
-
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
-
Form 6-K CYBIN INC. For: Dec 05
-
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
-
Form 6-K CYBIN INC. For: Nov 30
Back to CYBN Stock Lookup